Atea Pharmaceuticals to present data on bemnifosbuvir, ruzasvir combination

Atea Pharmaceuticals (AVIR) announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, as a potential best-in-class regimen for the treatment of hepatitis C infection at The Liver Meeting 2025, the annual meeting of the American Association for the Study of Liver Diseases. Accepted for presentations were three abstracts detailing multi-scale HCV modeling results and a viral resistance analysis both from the Phase 2 study evaluating the combination regimen of bemnifosbuvir and ruzasvir and results from a Phase 1 study investigating whether there is a food effect with the fixed-dose combination of bemnifosbuvir and ruzasvir. The Liver Meeting 2025 will take place November 7-11 in Washington, DC. Earlier this year, at the European Association for the Study of the Liver Congress 2025, Atea presented results from the full cohort of patients enrolled in its Phase 2 study evaluating the regimen. These results showed a robust 98% SVR12 with the regimen in the “Per-Protocol Treatment-Adherent Population.” The SVR12 rate was 95% in the “Per-Protocol Regardless of Adherence Population”, which included patients who were not treatment adherent. Results from three Phase 1 studies presented at the EASL Congress 2025 demonstrated that the combination of bemnifosbuvir and ruzasvir had a low risk of drug-drug interactions and supported the safety of the regimen in HCV patients co-infected with human immunodeficiency virus taking a standard HIV treatment, and the safety of bemnifosbuvir in participants with hepatic or renal impairment with no need for dose adjustments.